Medicare CBD News and Program Updates

Written by the Edify Wellness Team

The Medicare CBD program is active and evolving. Regulations are shifting, new legal challenges have emerged, and the number of patients and providers participating continues to grow. This page tracks the most important developments and explains what each one means for Medicare patients and healthcare providers.

For the full program background, start with our complete Medicare CBD guide. This page focuses on current developments.

The Program Is Live in All 50 States

The Substance Access Beneficiary Engagement Incentive (BEI) is currently operating through 74 ACO REACH organizations across all 50 states. Patients enrolled in a participating ACO can receive up to $500 per year in qualifying CBD products at no out-of-pocket cost.

The Enhancing Oncology Model is also active, with a specific focus on cancer patients. Both models are running under the CMS Innovation Center. A third model, the LEAD Model, has been announced as a future participant in the BEI framework.

The FDA Enforcement Discretion Memo

One of the key enabling actions for this program was the FDA's enforcement discretion memo. In it, the FDA stated it would not enforce certain prohibitions on oral hemp-derived CBD products being used within the BEI framework.

This matters because CBD technically occupies a gray area in FDA's regulatory structure. The FDA had previously taken the position that CBD couldn't be added to food or sold as a dietary supplement due to its prior drug approval pathway (Epidiolex). The enforcement discretion memo carved out a path specifically for products used within the CMS program.

This isn't a permanent change to FDA regulations. It's a policy decision not to enforce in specific circumstances. That distinction matters for the long-term picture.

Active Legal Challenge: The SAM Lawsuit

Smart Approaches to Marijuana (SAM), an advocacy organization opposed to cannabis policy reform, filed a lawsuit seeking to block the Medicare CBD program. The lawsuit argues the program oversteps CMS authority and that CBD distribution through Medicare constitutes illegal drug distribution.

The program continues to operate while the litigation works through the courts. Patients currently enrolled in the program are not at immediate risk of losing access. However, a court ruling against the program could force CMS to pause or restructure it.

This is the single largest legal risk to the program's continuity. It's worth monitoring, particularly for healthcare providers who are building workflows around the BEI.

Cornbread Hemp GPO Contract: What It Means for Patients

Cornbread Hemp secured an exclusive supplier contract through Alliant Purchasing, a Group Purchasing Organization (GPO) with relationships covering approximately 68,000 provider locations. This made Cornbread Hemp the first brand with a formal GPO arrangement for Medicare CBD supply.

Here's what this actually means: ACOs that use Alliant's purchasing contracts have an easy, pre-negotiated path to ordering Cornbread Hemp products. It's a significant market advantage.

Here's what it doesn't mean: ACOs are not required to use Alliant or Cornbread Hemp. Any product that meets CMS compliance standards can be used. ACOs that prefer to source independently can do so. The GPO contract is a purchasing convenience, not a mandate.

Edify's products meet the same CMS compliance standards. Our lab results are public. ACOs and healthcare providers can evaluate our products on the same criteria as any other compliant supplier.

Charlotte's Web Online Healthcare Portal

Charlotte's Web, another major CBD brand, announced plans to deliver qualifying products through an online healthcare portal that connects ACOs and patients. This distribution model is different from traditional wholesale supply chains and represents a potentially simpler path for ACOs to manage product fulfillment.

The specifics of how this portal works and when it becomes broadly available are still developing. It's a sign that the industry is investing in infrastructure to support the BEI program at scale.

Federal Hemp Law Is Changing

Federal hemp legislation is expected to change in ways that affect CBD products broadly. One major anticipated change is a cap on total THC per container (proposed at 0.4mg). If enacted, this would affect which products qualify under the BEI.

CMS has already acknowledged this and stated it will adjust program rules as federal law evolves. That's a meaningful signal that the program is designed to adapt, not shut down, when the legal environment changes.

For Edify, this is something we're actively monitoring. Our compliance approach is built on third-party testing and transparent labeling, which means we can verify and adjust to new requirements as they come.

Cannabis Rescheduling and What It Could Mean

An executive order has directed the rescheduling of marijuana from Schedule I to Schedule III under the Controlled Substances Act. This is about marijuana, not hemp, but the two are legally intertwined in ways that matter for CBD policy.

Schedule III status would significantly change how the DEA and FDA treat marijuana-derived cannabinoids. It wouldn't automatically change the regulatory status of hemp-derived CBD, but it would likely create political and regulatory momentum for clearer CBD rules overall.

This is a slow-moving development. Rescheduling involves multiple federal agencies, a comment period, and administrative review. It won't change the Medicare CBD program overnight, but it's part of a broader regulatory shift worth watching.

CMS Leadership Context

CMS is currently led by Dr. Mehmet Oz as Administrator, and the Department of Health and Human Services is led by Secretary Robert F. Kennedy Jr. Both have taken positions generally favorable to expanding non-pharmaceutical health interventions. That context matters for understanding why the BEI was launched and why it's likely to receive continued support at the administrative level, legal challenges notwithstanding.

What This Means for Patients Right Now

The program is live. It's expanding. There are legal risks, but the program continues to operate. Here's what patients should focus on:

Ask your doctor now if their practice participates in ACO REACH or the Enhancing Oncology Model
Don't wait for a future expansion. Access the benefit through your current care team if possible
If you can't access the benefit yet, Edify products are available for direct purchase and meet the same compliance standards

Products like our Soothe Recovery CBD Gummies and Relieve CBD & CBG Tincture, THC-Free are available now and ship to all 50 states. Our Subscribe & Save program keeps ongoing costs down.

About Edify's Compliance Approach

Edify isn't waiting on regulations to catch up. We've always operated as if every batch would be audited. Our hemp is grown on a USDA-certified organic family farm in Kentucky. Every product is independently tested by third-party labs, and the results are published publicly on our lab results page.

Our Seed-to-Self process gives us full traceability from hemp plant to finished product. That's the level of documentation healthcare providers and ACOs need to confidently source compliant products.

Your cart is currently empty.